摘要
术后辅助治疗能够提高乳腺癌病人的总生存率和无病生存率 ,含蒽环类药方案优于非蒽环类药方案 ,阿霉素为主方案中加入紫杉醇能进一步提高淋巴结阳性病人的生存率。化疗加用他莫昔芬(TAM)能进一步提高疗效。辅助化疗疗效与一定剂量强度相关 ,但强烈化疗联合造血干细胞移植似不能改善病人生存。新辅助化疗对Ⅲ期乳腺癌有效。合理应用内分泌治疗和化疗能改善晚期病人的生活质量。
This paper summarizes recent advances in systemic treatment of breast cancer.Adjuvant therapy can improve overall survival rate and disease_free survival of operable breast cancer.Used in the adjuvant therapy of breast cancer,anthracycline based regimens are superior to non anthracycline containing regimens.The addition of paclitaxel to Doxorubicin based therapy improves overall survival in node positive patients.The addition of tamoxifen to chemotherapy further improves survival in ER positive patients.Efficacy of chemotherapy is related to dose intensity,however,the use of high dose chemotherapy and stem cell transplant seems no survival improvement.Neoadjuvant chemotherapy may improve survival for patients with stageⅢ breast cancer.Reasonable use of endocrine therapy and chemotherapy can improve quality of life and prolong survival time for patients with advanced breast cancer.
出处
《肿瘤学杂志》
CAS
2001年第2期65-68,共4页
Journal of Chinese Oncology
关键词
药物疗法
治疗
乳腺癌
breast neoplasms
drug therapy
